Medication info
TruStar Tablet 40/10 mg

TruStar Tablet 40/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Bright blue oval film-coated tablets
Packaging
30 tablets (10 tablets x 3 PTP)
Approval status
Active

MFDS item code 201504135 · Approved 2015.06.25 · Insurance code 650303360

Summary

Main use
Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine provides additional blood pressure reduction when administered in combination with a thiazide diuretic such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. This medicine may be taken at any time of the day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same content of each active ingredient) for convenience.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who require simultaneous administration of both Telmisartan and Rosuvastatin. Telmisartan is primarily used for the treatment of essential hypertension and to reduce the risk of cardiovascular disease, particularly in high-risk patients who cannot use ACE inhibitors, lowering the risk of myocardial infarction, stroke, and cardiovascular disease-related mortality. Rosuvastatin effectively manages blood cholesterol and LDL cholesterol levels in patients with hypercholesterolemia or dyslipidemia, helping to slow the progression of atherosclerosis and reducing the risks of cardiovascular disease and stroke. The combination of these two medications plays an important role in managing cardiovascular disease risk and contributes to improving patients' health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine provides additional blood pressure reduction when administered in combination with a thiazide diuretic such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medicine orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. This medicine may be taken at any time of the day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Older adults: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product with the same content of each active ingredient) for convenience.

Precautions

This medication can cause severe harm to the fetus during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential should use appropriate contraceptive methods, and it is safer to avoid this medication during pregnancy or breastfeeding. Patients with severe liver or kidney dysfunction, certain muscle disorders, or hypersensitivity should not take this medication. Special caution is required for the elderly, patients with hyperkalemia, and those with liver impairment, and they should be managed carefully under a doctor's instructions. This medication can cause muscle-related side effects such as myalgia or myopathy, and in rare cases, rhabdomyolysis; therefore, if muscle pain or weakness occurs, consult a physician promptly. Regular liver function tests are important as liver dysfunction may occur. If symptoms of hypotension emerge, report them immediately to medical staff, as blood pressure may drop too low. This medication may interact with other drugs, so inform medical staff about any other medications being taken. Caution is necessary when driving or operating machinery as dizziness or drowsiness may occur. In case of overdose, seek immediate medical care and carefully monitor blood pressure, kidney function, liver function, and muscle condition. This medication is not recommended for children as its safety and efficacy have not been established. This medication contains lactose and should not be administered to patients with genetic lactose intolerance. Store out of reach of children and do not transfer to another container.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, painful urination, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver impairment, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, vascular edema, hypersensitivity reactions including vascular edema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia, ocular myasthenia, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, appetite loss, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, palpitations, fatigue, nausea, inadequate effect, cough, dyspepsia, palpitations, myalgia, increased CK, constipation, increased AST, numbness, sensory disturbances, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, arrhythmia, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine, hypotension, tachycardia, bradycardia, dizziness, acute kidney failure, hypoglycemia, weakness, hunger, cold sweat, tremors, decreased concentration, spasms, consciousness disturbance, blood pressure lowering, laryngeal edema, shock, loss of consciousness, jaundice, hepatitis, dyspnea, blood pressure lowering, laryngeal edema, interstitial pneumonia, fever, cough, abnormal chest X-ray, rhabdomyolysis, myalgia, weakness, increased myoglobin in serum and urine, palpitations, fatigue, nausea, inadequate effect, headache, dizziness, cough, dyspepsia, palpitations, increased ALT, chest pain, myalgia, increased CK, constipation, increased AST, weakness, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, severe skin adverse reaction, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, severe myasthenia, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This helps to preserve the medication's efficacy and safety over time.

Appearance and packaging

Appearance

Bright blue oval film-coated tablets

Package unit

30 tablets (10 tablets x 3 PTP)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.